Treatment for Stable COPD

Asthma and COPD

Volumn , Issue , 2009, Pages 823-836

  Rennard, Stephen I ^a  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882832481     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-12-374001-4.00066-3     Document Type: Chapter

References (138)

1. Celli BR, MacNee W Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper. Eur Respir J 2004, 23(6):932-946.
2. GOLD Executive and Science Committees, a, G.E., S. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, 2007.
3. Siafakas NM, Vermeire P, Pride NP, Paoletti P, Gibson J, Howard P, Yernault JC, Decramer M, Higenbottam T, Postma DS, Rees J Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur Respir J 1995, 8:1398-1420.
4. ten Brinke A Risk factors associated with irreversible airflow limitation in asthma. Curr Opin Allergy Clin Immunol 2008, 8(1):63-69.
5. Bai TR, Vonk JM, Postma DS, Boezen HM Severe exacerbations predict excess lung function decline in asthma. Eur Respir J 2007, 30(3):452-456.
6. Coxson HO, Rogers RM, Whittall KP, D'Yachkova Y, Pare PD, Sciurba FC, Hogg JC A quantification of the lung surface area in emphysema using computed tomography. Am J Respir Crit Care Med 1999, 159(3):851-856.
7. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J 2002, 20(5):1117-1122.
8. Hnizdo E, Glindmeyer HW, Petsonk EL, Enright P, Buist AS Case definitions for chronic obstructive pulmonary disease. COPD 2006, 3(2):95-100.
9. Mannino DM, Gagnon RC, Petty TL, Lydick E Obstructive lung disease and low lung function in adults in the United States: Data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000, 160(11):1683-1689.
10. Qaseem A, Snow V, Shekelle P, Sherif K, Wilt TJ, Weinberger S, Owens DK Diagnosis and management of stable chronic obstructive pulmonary disease: A clinical practice guideline from the American College of Physicians. Ann Intern Med 2007, 147(9):633-638.
11. Rennard S, Decramer M, Calverley PM, Pride NB, Soriano JB, Vermeire PA, Vestbo J Impact of COPD in North America and Europe in 2000: Subjects' perspective of Confronting COPD International Survey. Eur Respir J 2002, 20(4):799-805.
12. Jones PW Issues concerning health-related quality of life in COPD. Chest 1995, 107(5 Suppl):187S-193S.
13. Schols AM, Mostert R, Soeters PB, Wouters EF Body composition and exercise performance in patients with chronic obstructive pulmonary disease. Thorax 1991, 46(10):695-699.
14. Celli BR, Calverley PMA, Rennard SI, Wouters MEF. Submitted. Proposal for a new staging system for chronic obstructive pulmonary disease.
15. Wegner RE, Jorres RA, Kirsten DK, Magnussen H Factor analysis of exercise capacity, dyspnoea ratings and lung function in patients with severe COPD. Eur Respir J 1994, 7(4):725-729.
16. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, Cabral HJ The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Engl J Med 2004, 350(10):1005-1012.
17. Cote CG, Celli BR Pulmonary rehabilitation and the BODE index in COPD. Eur Respir J 2005, 26(4):630-636.
18. Celli BR Change in the BODE index reflects disease modification in COPD: Lessons from lung volume reduction surgery. Chest 2006, 129(4):835-836.
19. Vestbo J, Anderson W, Coxson HO, Crim C, Dawber F, Edwards L, Hagan G, Knobil K, Lomas DA, Macnee W, Silverman EK, Tal-Singer R Evaluation of COPD longitudinally to identify predictive surrogate endpoints (ECLIPSE). Eur Respir J 2008.
20. SPIROMICS, 2007.
21. Shapiro SD, Snider GL, Rennard SI Chronic bronchitis and emphysema. Textbook of Respiratory Medicine 2005, 1115-1167. Elsevier, Philadelphia, PA. 4th edn. R.J. Mason, V.C. Broadus, J.F. Murray, J.A. Nadel (Eds.).
22. Fiore M, Bailey W, Cohen S, Dorfman S, Goldstein M, Gritz E, Heyman R, Jaen C, Kottke T, Lando H, Mecklenburg R, Mullen P, Nett L, Robinson L, Sistzer M, Tommasello A, Villejo L, Wewers M Treating Tobacco Use and Dependence 2000, U.S. Department Of Health and Human Services, Rockville, MD.
23. Fiore MC. Treating Tobacco Use and Dependence. Department of Health and Human Services.
24. Clearing the Smoke. Washington DC: National Academy Press, 2001.
25. Shiffman S, Hickcox M, Paty JA, Gnys M, Kassel JD, Richards TJ Progression from a smoking lapse to relapse: Prediction from abstinence violation effects, nicotine dependence, and lapse characteristics. J Consult Clin Psychol 1996, 64(5):993-1002.
26. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Enright PL, Kanner RE, O'Hara P, Owens GR, Scanlon PD, Tashkin DP, Wise RA Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. JAMA 1994, 272:1497-1505.
27. Tashkin D, Kanner R, Bailey W, Buist S, Anderson P, Nides M, Gonzales D, Dozier G, Patel KM, Jamerson B Smoking cessation in patients with chronic obstructive pulmonary disease: A double-blind, placebo-controlled, randomised trial. Lancet 2001, 357(9268):1571-1575.
28. Buist AS, Sexton GJ, Nagy JM, Ross BB The effect of smoking cessation and modification on lung function. Am Rev Respir Dis 1976, 114:115-122.
29. Fiore MC, Bailey WC, Cohen SJ. Smoking cessation. Guideline technical report no. 18. Rockville, MD: U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research. Publication No. AHCPR 97-Noo4, October 1997.
30. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. N Engl J Med 1999, 340:1948-1953.
31. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K Long-term effect of inhaled budesonide in mild and moderate chronic obstructive pulmonary disease: A randomised controlled trial. Lancet 1999, 353(9167):1819-1823.
32. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial. BMJ 2000, 320(7245):1297-1303.
33. Sutherland ER, Allmers H, Ayas NT, Venn AJ, Martin RJ Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis. Thorax 2003, 58(11):937-941.
34. 1 in patients with chronic obstructive pulmonary disease. A meta-analysis. Ann Intern Med 2003, 138(12):969-973.
35. Calverley PM, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007, 356(8):775-789.
36. Celli BR, Thomas NE, Anderson JA, Ferguson GT, Jenkins C, Jones PW, Vestbo J, Knobil K, Yates JC, Calverley PM Effect of pharmacotherapy on rate of decline of lung function in COPD: Results from the TORCH study. Am J Respir Crit Care Med 2008.
37. Anzueto A, Tashkin D, Menjoge S, Kesten S One-year analysis of longitudinal changes in spirometry in patients with COPD receiving tiotropium. Pulm Pharmacol Ther 2005, 18(2):75-81.
38. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S Clinical trial design considerations in assessing long-term functional impacts of tiotropium in COPD: The UPLIFT trial. COPD 2004, 1(2):303-312.
39. Tashkin DP, Detels R, Simmons M, Liu H, Coulson AH, Sayre J, Rokaw S The UCLA population studies of chronic obstructive respiratory disease: XI. Impact of air pollution and smoking on annual change in forced expiratory volume in one second. Am J Respir Crit Care Med 1994, 149(5):1209-1217.
40. Kauffmann F, Drouet D, Lelouch J Occupational exposure and 12-year spirometric changes among Paris area workers. Brit J Industr Med 1982, 39:221-232.
41. Samet JM, Marbury MC, Spengler JD Health effects and sources of indoor air pollution. Part II. Am Rev Respir Dis 1988, 137(1):221-242.
42. Samet JM, Marbury MC, Spengler JD Health effects and sources of indoor air pollution Part I. Am Rev Respir Dis 1987, 136(6):1486-1508.
43. Samet JM, Dominici F, Curriero FC, Coursac I, Zeger SL Fine particulate air pollution and mortality in 20 U.S. cities, 1987-1994. N Engl J Med 2000, 343(24):1742-1749.
44. Peters A, Liu E, Verrier RL, Schwartz J, Gold DR, Mittleman M, BaliffJ, Oh JA, Allen G, Monahan K, Dockery DW Air pollution and incidence of cardiac arrhythmia. Epidemiology 2000, 11(1):11-17. [see comments].
45. Samet J, Tager I The relationship between respiratory illness in childhood and chronic air-flow obstruction in adulthood. Am Rev Respir Dis 1983, 127:508-523.
46. Hogg JC Latent adenoviral infection in the pathogenesis of emphysema: The Parker B. Francis Lectureship. Chest 2000, 117(5 Suppl 1):282S-285S.
47. 1 decline and chronic obstructive pulmonary disease morbidity. Am J Respir Crit Care Med 1996, 153:1530-1535.
48. McElvaney NG, Crystal RG Proteases and lung injury. The Lung: Scientific Foundations 1997, Lippincott-Raven, Philadelphia, PA.
49. 1-antitrypsin. Am J Respir Crit Care Med 1998, 158:49-59.
50. Seersholm N, Wencker M, Banik N, Viskum K, Dirksen A, Kok-Jensen A, Konietzko N Does alpha1-antitrypsin augmentation therapy slow the annual decline in FEV1 in patients with severe hereditary alpha1-antitrypsin deficiency? Wissenschaftliche Arbeitsgemeinschaft zur Therapie von Lungenerkrankungen (WATL) alpha1-AT study group. Eur Respir J 1997, 10(10):2260-2263.
51. Dirksen A, Dijkman JH, Madsen F, Stoel B, Hutchison DC, Ulrik CS, Skovgaard LT, Kok-Jensen A, Rudolphus A, Seersholm N, Vrooman HA, Reiber JH, Hansen NC, Heckscher T, Viskum K, Stolk J A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J Respir Crit Care Med 1999, 160(5 Pt 1):1468-1472.
52. Abboud RT, Ford GT, Chapman KR Alpha1-antitrypsin deficiency: A position statement of the Canadian Thoracic Society. Can Respir J 2001, 8(2):81-88.
53. Lieberman J Augmentation therapy reduces frequency of lung infections in antitrypsin deficiency: A new hypothesis with supporting data. Chest 2000, 118(5):1480-1485.
54. Mahler DA. Ramirez-Venegas A. 1Dyspnoea. In: Principles and Practice of Geriatric Medicine 3rd edn, pp. 655-662.
55. O'Donnell DE Dyspnea in advanced chronic obstructive pulmonary disease. J Heart Lung Transplant 1998, 17(6):544-554.
56. Mahler DA Dyspnoea in chronic obstructive pulmonary disease. Monaldi Arch Chest Dis 1998, 53(6):669-671.
57. Gorini M, Misuri G, Corrado A, Duranti R, Iandelli I, De Paola E, Scano G Breathing pattern and carbon dioxide retention in severe chronic obstructive pulmonary disease. Thorax 1996, 51:677-683.
58. O'Donnell DE, Lam M, Webb KA Measurement of symptoms, lung hyperinflation, endurance during exercise in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 158(5 Pt 1):1557-1565.
59. O'Donnell DE, Bertley JC, Chau LK, Webb KA Qualitative aspects of exertional breathlessness in chronic airflow limitation. Am J Respir Crit Care Med 1997, 1555:109-115.
60. O'Donnell DE, Lam M, Webb KA Spirometric correlates of improvement in exercise performance after anticholinergic therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999, 160(2):542-549.
61. O'Donnell DE Assessment of bronchodilator efficacy in symptomatic COPD: Is spirometry useful?. Chest 2000, 117(2 Suppl):42S-47S.
62. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Kesten S Improvement in exercise tolerance with the combination of tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005, 127(3):809-817.
63. Anthonisen NR, Wright E Bronchodilator response in chronic obstructive pulmonary disease. Am Rev Respir Dis 1986, 133:814-819.
64. Rennard SI, Serby CW, Ghafouri M, Johnson PA, Friedman M Extended therapy with ipratropium is associated with improved lung function in COPD: A retrospective analysis of data from seven clinical trials. Chest 1996, 110:62-70.
65. Calverley PM, Burge PS, Spencer S, Anderson JA, Jones PW Bronchodilator reversibility testing in chronic obstructive pulmonary disease. Thorax 2003, 58(8):659-664.
66. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999, 115(4):957-965.
67. Rennard SI, Anderson W, Zu WR, Broughton J, Bailey W, Friedman M, Wisniewski M, Rickard K Use of a long-acting inhaled beta(2)-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(5):1087-1092.
68. Calverley PM Dynamic hyperinflation: Is it worth measuring?. Proc Am Thorac Soc 2006, 3(3):239-244.
69. van Beerendonk I, Mesters I, Mudde AN, Tan TD Assessment of the inhalation technique in outpatients with asthma or chronic obstructive pulmonary disease using a metered-dose inhaler or dry powder device. J Asthma 1998, 35(3):273-279.
70. Dompeling E, Van Grunsven PM, Van Schayck CP, Folgering H, Molema J, Van Weel C Treatment with inhaled steroids in asthma and chronic bronchitis: Long-term compliance and inhaler technique. Fam Pract 1992, 9(2):161-166.
71. Gray SL, Williams DM, Pulliam CC, Sirgo MA, Bishop AL, Donohue JF Characteristics predicting incorrect metered-dose inhaler technique in older subjects. Arch Intern Med 1996, 156(9):984-988.
72. Tan NC, Ng CJ, Goh S, Lee CE Assessment of metered dose inhaler technique in family health service patients in Singapore. Singapore Med J 1999, 40(7):465-467.
73. Guthrie SJ, Hill KM, Muers ME Living with severe COPD. A qualitative exploration of the experience of patients in Leeds. Respir Med 2001, 95(3):196-204.
74. Ikeda A, Nishimura K, Koyama H, Tsukino M, Hajiro T, Mishima M, Izumi T Comparison of the bronchodilator effects of salbutamol delivered via a metered-dose inhaler with spacer, a dry-powder inhaler, a jet nebulizer in patients with chronic obstructive pulmonary disease. Respiration 1999, 66(2):119-123.
75. Balzano G, Battiloro R, Biraghi M, Stefanelli F, Fuschillo S, Gaudiosi C, De Angelis E Effectiveness and acceptability of a domiciliary multidrug inhalation treatment in elderly patients with chronic airflow obstruction: Metered dose inhaler versus jet nebulizer. J Aerosol Med 2000, 13(1):25-33.
76. O'Driscoll BR, Bernstein A A long-term study of symptoms, spirometry and survival amongst home nebulizer users. Respir Med 1996, 90(9):561-566.
77. Tenholder MG, Bryson MJ, Waller RF, et al. Can MDIs be used effectively by extubated ICU patients?. Am J Med 1992, 77:834-838.
78. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone. Chest 1994, 105:1411-1419. Group, CIAS.
79. Routine nebulized ipratropium and albuterol together are better than either alone in COPD. Chest 1997, 112:1514-1521. Group, CISS.
80. Rennard SI Anticholinergics in combination bronchodilator therapy in COPD. Anticholinergic Agents in the Upper and Lower Airways 1999, 119-136. Marcel Dekker, Inc, New York. S.L. Spector (Ed.).
81. Rabe KF, Dent G Theophylline. Asthma 1997, 1535-1554. Lippincott-Raven, Philadelphia, PA. P.J. Barnes, M.M. Grunstein, A.R. Leff, A.J. Woolcock (Eds.).
82. Combination Therapy for Asthma and Chronic Obstructive Pulmonary Disease. New York: Marcel Dekker, 2000.
83. van Noord JA, Aumann JL, Janssens E, Smeets JJ, Verhaert J, Disse B, Mueller A, Cornelissen PJ Comparison of tiotropium once daily, formoterol twice daily and both combined once daily in patients with COPD. Eur Respir J 2005, 26(2):214-222.
84. van Noord JA, de Munck DR, Bantje TA, Hop WC, Akveld ML, Bommer AM Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000, 15(5):878-885.
85. Roberts AB, Lamb LC, Newton DL, Sporn MB, De Larco JE, Todaro GJ Transforming growth factors: Isolation of polypeptides from virally and chemically transformed cells by acid/ethanol extraction. Proc Natl Acad Sci USA 1980, 77:3494-3498.
86. Nishimura K, Koyama H, Ikeda A, Sugiura N, Kawakatsu K, Izumi T The additive effect of theophylline on a high-dose combination of inhaled salbutamol and ipratropium bromide in stable COPD. Chest 1995, 107:718-723.
87. Rennard SI, Calverley P Rescue! Therapy and the paradox of the Barcalounger. Eur Respir J 2003, 21(6):916-917.
88. Cook D, Guyatt G, Wong E, Goldstein R, Bedard M, Austin P, Ramsdale H, Jaeschke R, Sears M Regular versus as-needed short-acting inhaled beta-agonist therapy for chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001, 163(1):85-90.
89. Celli BR, Snider GL, Heffner J, Tiep B, Ziment I, Make B, Braman S, Olsen G, Phillips Y Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1995, 152:S77-S120.
90. Rennard SI Treatment of stable chronic obstructive pulmonary disease. Lancet 2004, 364(9436):791-802.
91. Calverley PM, Rennard SI What have we learned from large drug treatment trials in COPD?. Lancet 2007, 370(9589):774-785.
92. Jarad NA, Wedzicha JA, Burge PS, Calverley PM An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999, 93(3):161-166.
93. Ries AL, BauldoffGS, Carlin BW, Casaburi R, Emery CF, Mahler DA, Make B, Rochester CL, Zuwallack R, Herrerias. C Pulmonary rehabilitation: Joint ACCP/AACVPR evidence-based clinical practice guidelines. Chest 2007, 131(5 Suppl):4S-42S.
94. Berry MJ, Rejeski WJ, Adair NE, Zaccaro D Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am J Respir Crit Care Med 1999, 160(4):1248-1253.
95. Leung R, Hill P, Burdon J Effect of inhaled morphine on the development of breathlessness during exercise in patients with chronic lung disease. Thorax 1996, 51:596-600.
96. Light RW, Stansbury DW, Webster JS Effect of 30mg of morphine alone or with promethazine or prochlorperazine on the exercise capacity of patients with COPD. Chest 1996, 109:975-981.
97. Masood AR, Reed JW, Thomas SHL Lack of effect of inhaled morphine on exercise-induced breathlessness in chronic obstructive pulmonary disease. Thorax 1995, 50:629-634.
98. Poole PJ, Veale AG, Black PN The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998, 157(6 Pt 1):1877-1880.
99. Eiser N, Denman WT, West C, Luce P Oral diamorphine: Lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. Eur Respir J 1991, 4(8):926-931.
100. Young IH, Daviskas E, Keena VA Effect of low dose nebulised morphine on exercise endurance in patients with chronic lung disease. Thorax 1989, 44(5):387-390.
101. Cooper JD, Trulock EP, Triantafillou AN, Patterson GA, Pohl MS, Deloney PA, Sundaresan RS, Roper CL Bilateral pneumectomy (volume reduction) for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1995, 109:106-119.
102. Brenner M, McKenna RJ, Gelb AF, Fischel RJ, Wilson AF Rate of FEV change following lung volume reduction surgery. Chest 1998, 113:652-659.
103. Lando Y, Boiselle P, Shade D, Travaline JM, Furukawa S, Criner GJ Effect of lung volume reduction surgery on bony thorax configuration in severe COPD. Chest 1999, 116(1):30-39.
104. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood DE A randomized trial comparing lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 2003, 348(21):2059-2073.
105. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Novick RJ The registry of the International Society for Heart and Lung Transplantation: Fourteenth official report - 1997. J Heart Lung Transplant 1997, 16(7):691-712.
106. Hosenpud JD, Bennett LE, Keck BM, Fiol B, Boucek MM, Novick RJ The Registry of the International Society for Heart and Lung Transplantation: Fifteenth official report - 1998. J Heart Lung Transplant 1998, 17(7):656-668.
107. Ziment I Historic overview of mucoactive drugs. Drugs in Bronchial Mucology 1989, 1-33. Raven Press, New York. P.C. Braga, L. Allegra (Eds.).
108. Decramer M, Rutten-van Molken M, Dekhuijzen PN, Troosters T, van Herwaarden C, Pellegrino R, van Schayck CP, Olivieri D, Del Donno M, De Backer W, Lankhorst I, Ardia A Effects of N-acetylcysteine on outcomes in chronic obstructive pulmonary disease (Bronchitis Randomized on NAC Cost-Utility Study, BRONCUS): A randomised placebo-controlled trial. Lancet 2005, 365(9470):1552-1560.
109. Irwin RS, Curley FJ, Pratter MR The effects of drugs on cough. Eur J Respir Dis Suppl 1987, 153:173-181.
110. Engelen MP, Schols AM, Lamers RJ, Wouters EF Different patterns of chronic tissue wasting among patients with chronic obstructive pulmonary disease. Clin Nutr 1999, 18(5):275-280.
111. Casaburi R Skeletal muscle function in COPD. Chest 2000, 117(5 Suppl 1):267S-271S.
112. Nici L Mechanisms and measures of exercise intolerance in chronic obstructive pulmonary disease. Clin Chest Med 2000, 21(4):693-704.
113. Casaburi R Rationale for anabolic therapy to facilitate rehabilitation in chronic obstructive pulmonary disease. Baillieres Clin Endocrinol Metab 1998, 12(3):407-418.
114. Borson S, Claypoole K, McDonald GJ Depression and chronic obstructive pulmonary disease: Treatment trials. Semin Clin Neuropsychiatry 1998, 3(2):115-130.
115. Fried TR, Pollack DM, Tinetti ME Factors associated with six-month mortality in recipients of community-based long-term care. J Am Geriatr Soc 1998, 46(2):193-197.
116. Jones PW, Quirk FH, Baveystock CM, Littlejohns P A self-complete measure of health status for chronic airflow limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992, 145(6):1321-1327.
117. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987, 42:773-778.
118. Jones PW, Bosh TK Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997, 155:1283-1289.
119. Appleton S, Smith B, Veale A, Bara A Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2000, 2.
120. Sin DD, McAlister FA, Man SF, Anthonisen NR Contemporary management of chronic obstructive pulmonary disease: Scientific review. JAMA 2003, 290(17):2301-2312.
121. Grandjean EM, Berthet P, Ruffmann R, Leuenberger P Efficacy of oral long-term N-acetylcysteine in chronic bronchopulmonary disease: A meta-analysis of published double-blind, placebo-controlled clinical trials. Clin Ther 2000, 22(2):209-221.
122. Stey C, Steurer J, Bachmann S, Medici TC, Tramer MR The effect of oral N-acetylcysteine in chronic bronchitis: A quantitative systemitic review. Eur Respir J 2000, 16:253-262.
123. Collet JP, Shapiro P, Ernst P, Renzi T, Ducruet T, Robinson A Effects of an immunostimulating agent on acute exacerbations and hospitalizations in patients with chronic obstructive pulmonary disease, The PARI_IS Study steering committee and research group. Prevention of acute respiratory infection by an immunostimulant. Am J Respir Crit Care Med 1997, 156:1719-1724.
124. Stuart-Harris C, Bishop JM, Clark TJH, Dornhorst AC, Cotes JE, Flenley DC, Howard P, Oldham PD Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema. Lancet 1981, 1:681-686.
125. Kvale PA, Cugell DW, Anthonisen NR, Timms RM, Petty TL, Boylen CT Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease. Ann Intern Med 1980, 93:391-398.
126. Cooper JA. Kinetics of pulmonary inflammatory mediator production during development of cyclophosphamide-induced pulmonary injury.
127. Strom K Survival of patients with chronic obstructive pulmonary disease receiving long-term domiciliary oxygen therapy. Am Rev Respir Dis 1993, 147(3):585-591.
128. Carrera M, Sauleda J, Bauza F, Bosch M, Togores B, Barbe F, Agusti AG The results of the operation of a monitoring unit for home oxygen therapy. Arch Bronconeumol 1999, 35(1):33-38.
129. Rennard S, Carrera M, Agusti AGN Management of chronic obstructive pulmonary disease: Are we going anywhere?. Eur Respir J 2000, 16:1035-1036.
130. Sin DD, Man SF Pharmacotherapy for mortality reduction in chronic obstructive pulmonary disease. Proc Am Thorac Soc 2006, 3(7):624-629.
131. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005, 60(12):992-997.
132. Sin DD, Wu L, Man SF The relationship between reduced lung function and cardiovascular mortality: A population-based study and a systematic review of the literature. Chest 2005, 127(6):1952-1959.
133. Salpeter S, Ormiston T, Salpeter E Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005, (4). CD003566.
134. Mancini GB, Etminan M, Zhang B, Levesque LE, FitzGerald JM, Brophy JM Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006, 47(12):2554-2560.
135. Ishida W, Kajiwara T, Ishii M, Fujiwara F, Taneichi H, Takebe N, Takahashi K, Kaneko Y, Segawa I, Inoue H, Satoh J Decrease in mortality rate of chronic obstructive pulmonary disease (COPD) with statin use: A population-based analysis in Japan. Tohoku J Exp Med 2007, 212(3):265-273.
136. Soyseth V, Brekke PH, Smith P, Omland T Statin use is associated with reduced mortality in COPD. Eur Respir J 2007, 29(2):279-283.
137. Keddissi JI, Younis WG, Chbeir EA, Daher NN, Dernaika TA, Kinasewitz GT The use of statins and lung function in current and former smokers. Chest 2007, 132(6):1764-1771.
138. Reinke LF, Engelberg RA, Shannon SE, Wenrich MD, Vig EK, Back AL, Curtis JR Transitions regarding palliative and end-of-life care in severe chronic obstructive pulmonary disease or advanced cancer: Themes identified by patients, families, clinicians. J Palliat Med 2008, 11(4):601-609.